R&D channel feed

Te­va hit by an­oth­er PhI­II set­back on CGRP pain drug fre­manezum­ab, but there’s no pulling back now as ri­vals race ahead

8 years ago

In the glare of an in­tense gene ther­a­py spot­light, blue­bird con­tin­ues to tout each small step for­ward for its pi­o­neer­ing Lenti­Glo­bin

8 years ago

Re­searchers out­line an­oth­er big dis­ease tar­get for No­var­tis’ canakinum­ab as drug slash­es rate of gout flares

8 years ago

GSK, Vi­iV of­fer sneak peek of PhI­II da­ta on in-house two-drug HIV com­bo, tout­ing non-in­fe­ri­or­i­ty

8 years ago

New Jer­sey dan­gles tax sav­ings in front of Te­va in bid to bag US HQ as re­vamp costs 200-plus jobs

8 years ago

Ei­sai is build­ing a be­spoke Cam­bridge re­search cen­ter with a $100M-plus plan to find new ways to tack­le Alzheimer's

8 years ago

Flex sends out an SOS sig­nal, scrap­ping stud­ies and slash­ing staff as it hunts a sur­vival strat­e­gy — shares crater

8 years ago

Lit­tle vTv Ther­a­peu­tics adds an­oth­er round of bad da­ta on Alzheimer's drug, but they still love their chances

8 years ago

Galmed's stock rock­ets up as ex­ecs tout a mixed set of NASH da­ta

8 years ago

Roche CEO Sev­erin Schwan isn’t about to tam­per with a win­ning R&D strat­e­gy now, but he’s still look­ing for ways to cut costs

8 years ago

PhI­II Alzheimer’s drug goes bust — and a ma­jor set­back at Eli Lil­ly and As­traZeneca may doom the class

8 years ago

Sanofi builds on mR­NA al­liances with an $805M pact for Ron Re­naud’s Trans­late Bio

8 years ago
Pharma

Strike two: Vi­cal says an­oth­er one of its vac­cines has crashed and burned in PhII

8 years ago

Vi­su­al­ize: AS­CO 2018's win­ners and losers

8 years ago
Pharma

Af­ter snatch­ing up Shire's can­cer unit, French phar­ma gi­ant Servi­er to ex­pand US pres­ence with Kendall Square in­no­va­tion of­fice

8 years ago

Di­a­betes gi­ant No­vo said to con­sid­er up to 3,000 lay­offs as US pric­ing storms gath­er: re­port

8 years ago
Pharma

Re­lo­cat­ing its US HQ to Boston, French phar­ma Ipsen to add 250 jobs

8 years ago
Pharma

Gates Foun­da­tion sets up biotech-like in­sti­tute in hands-on ef­fort to spur drug de­vel­op­ment for ne­glect­ed dis­eases

8 years ago
Pharma

Bio­gen, Ei­sai BACE drug cuts amy­loid be­ta in the brain, but there’s no hard da­ta to show it does any­thing im­por­tant for cog­ni­tion

8 years ago

Pick­ing up the pieces left from an Alzheimer’s im­plo­sion, Ax­o­vant is start­ing over by div­ing in­to gene ther­a­py

8 years ago
Pharma

Gilead ups its bet on HIV, hep B, ink­ing $400M part­ner­ship with im­munother­a­py com­pa­ny Hookipa

8 years ago
Pharma

#AS­CO18: Ab­b­Vie con­vinces one top an­a­lyst that its $6B 'megablock­buster' Ro­va-T is worth­less

8 years ago

Vaxart re­ports PhII de­feat for a lega­cy an­tivi­ral from Avi­ra­gen — shares slide

8 years ago

#AS­CO18: Bris­tol-My­ers takes an­oth­er stab at a pos­i­tive im­pres­sion for Check­Mate-227

8 years ago
First page Previous page 272273274275276277278 Next page Last page
A service from the Financial Times